Lantheus Holdings, Inc. (LNTH) News

Lantheus Holdings, Inc. (LNTH): $90.52

3.20 (+3.66%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

B

Filter LNTH News Items

LNTH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LNTH News Highlights

  • LNTH's 30 day story count now stands at 6.
  • Over the past 16 days, the trend for LNTH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DEC are the most mentioned tickers in articles about LNTH.

Latest LNTH News From Around the Web

Below are the latest news stories about LANTHEUS HOLDINGS INC that investors may wish to consider to help them evaluate LNTH as an investment opportunity.

New Year, New Gains: The 3 Best AI Stocks to Buy in 2024

These AI stocks offer substantial upside potential compared to the overextended chip players that dominated the theme in 2023.

Omor Ibne Ehsan on InvestorPlace | January 1, 2024

13 Most Promising Future Stocks To Buy According To Hedge Funds

In this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds. If you want to skip our overview of the latest stock market news, then you can take a look at the 5 Most Promising Future Stocks To Buy. Investing, for the most part, is all […]

Yahoo | December 27, 2023

Lantheus Holdings Is Charting a Path to Sustainable Growth and Value

Evaluating a leader in the global precision diagnostics market

Yahoo | December 20, 2023

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) BEDFORD, Mass., and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- December 18, 2023 – Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced statistically significant topline results from the pivotal Phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific m

Yahoo | December 18, 2023

Lantheus Holdings (LNTH) Crossed Above the 200-Day Moving Average: What That Means for Investors

Should investors be excited or worried when a stock crosses above the 200-day simple moving average?

Yahoo | December 15, 2023

Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It

Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Yahoo | December 12, 2023

Lantheus Holdings (LNTH) Recently Broke Out Above the 20-Day Moving Average

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Yahoo | December 11, 2023

Investors Heavily Search Lantheus Holdings, Inc. (LNTH): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Lantheus Holdings (LNTH). This makes it worthwhile to examine what the stock has in store.

Yahoo | November 29, 2023

Investors Met With Slowing Returns on Capital At Lantheus Holdings (NASDAQ:LNTH)

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...

Yahoo | November 22, 2023

Here is What to Know Beyond Why Lantheus Holdings, Inc. (LNTH) is a Trending Stock

Zacks.com users have recently been watching Lantheus Holdings (LNTH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Yahoo | November 17, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!